arrow
A

Adriana Rossi

ica hn school of medicine at mount sinai
H指数:23
被引数:1,827

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression

Cilta-Cel治疗多发性骨髓瘤后的长期缓解与多样化的T细胞和较低的髓系抑制相关

2025-11-070
OAAI
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia

BCMA定向嵌合抗原受体T细胞疗法治疗浆细胞白血病的有效性与安全性

2025-09-010
OAAI
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the US Multiple Myeloma Immunotherapy Consortium

复发难治性多发性骨髓瘤(RRMM)老年患者接受teclistamab治疗后的结局:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-05-090
OA
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma

髓外疾病而非骨旁疾病预示着CAR T细胞疗法在多发性骨髓瘤中的不良结局。

2025-05-030
PRE
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
2024-09-162
OAAI
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
2024-07-241
OAAI
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

髓外多发性骨髓瘤对idecabtagene vicleucel预后的影响

2024-06-063
OAAI
Post CAR-T lymphocytosis as a surrogate of BCMA CAR-T expansion, response, and prognosis in multiple myeloma
2024-03-220
PRE
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
2024-01-093
OAAI
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience

多发性骨髓瘤BCMA嵌合抗原受体T细胞槽分配的伦理挑战: 多机构经验

2023-04-0138
OAAI
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
2023-03-2126
OAAI
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach
2023-01-013
PRE